



#### OECEI PROJECTS AND INITIATIVES

Bench-can application submitted to the DG Health and Consumer Protection

OECEI and European Alliance for Personalised Medicine

Proposal for the constitution of a European Collaborative Group on Cancer Survivorship (ECGCS)

OECEI European Award for cancer policies

#### OECEI WORKING GROUPS

Launching of a new Working Group on Cost-Benefit OECEI Accreditation and Designation System formally presented in Rome at the Ministry for Health: Italian CCCs ready to enter as a group the OECEI recognition of excellence

Instituto Português de Oncologia de Coimbra Francisco Gentil recived the accreditation certificate

Professor Giorgio Stanta engaged to present a working programme to re-launch the molecular pathology and biobanks WG

START-OECEI attended the ECCO guidelines meeting in Brussels

OECEI-Clinical Trial Enterprise (OECEI-CTE) Working Group

#### GENERAL ASSEMBLIES AND MEMBERSHIP

34th OECEI General Assembly in Berlin – Joining the European Forum on Oncology - The partnership is confirmed for EFO 2013 Brussels

2013 OECEI General Assembly - Brussels – May 15th 2013

The OECEI welcomes three new members

– The Danish Cancer Society Research Centre (DCRC)

– The IRCCS Azienda Ospedaliera Universitaria San Martino – IST

– The National Koranyi Institute of TB and Pulmonology

#### OECEI EDUCATION

2nd EACR-OECEI Molecular Pathology Course

Third edition of the Biobanking and Molecular Pathobiology training course in Cluj

Survivorship conference in Bari

#### Dear OECEI Members,

Many of you were present at the Berlin Annual Meeting and General Assembly of the OECEI, which was organised with the European Oncology Forum. Although institutions in many European countries are facing financial difficulties, a major part of the OECEI members is actively involved in our Organisation. In this newsletter you will find a résumé of the most important developments. I would like to add two important issues that were discussed during the last OECEI Board meeting. The first is the communication with DG SANCO and the European Agency for Health and Consumers with whom we have discussed the position of the OECEI and their presence at the General Assembly in Brussels May 15th, 2013, which will again be organised in cooperation with the European Forum on Oncology.

The second important policy issue is the decision to ramp up efforts in education and on the involvement of Eastern and Southern European Members. We are exploring possibilities to cooperate in this regard with ESO and ECCO. To underline the importance of this effort it was decided to have the 2014 OECEI General Assembly and Scientific Conference in Cluj, Rumania.

The OECEI Board wants to thank you for your participation in all activities. We look forward to a further and strengthened involvement of your organisations in various new OECEI activities that will be starting such as the Health Economics Cost Effectiveness Working Group, the Working Group on Prevention or to take the decision to enter the Accreditation Programme. We especially welcome candidate auditors as we foresee a significant number of new accreditation applicants.



**Wim H. van Harten**  
OECEI President

#### Editors:

Wim van Harten and Claudio Lombardo

#### Editorial Office:

Margherita Marincola, Giorgia Pesce and Georgette Van Velzen



**OEI  
WORKING GROUP  
2012**



**Accreditation and Designation**

Mahasti Saghatchian  
Paris, France



**Biobanks and Molecular Pathobiology**

Giorgio Stanta  
Trieste, Italy



**Communication and Dissemination**

Gordon McVie  
Milan, Italy



Claudio Lombardo  
Genoa, Italy



**Cost - Benefit**

Lotte Steuten  
Amsterdam, The Netherlands



**Education & Training**

Angelo Paradiso  
Bari, Italy



**EurocanPlatform**

Ulrik Ringborg  
Stockholm, Sweden



**Prevention and Early Diagnosis**

Chris Harrison  
Manchester, United Kingdom



**START-OECI**

Lisa Licitra  
Milan, Italy

## Bench-can application submitted to the DG Health and Consumer Protection

An application titled Benchmarking comprehensive cancer care that provides interdisciplinary treatment for patients, and yield examples of best practice in comprehensive cancer care, has been submitted to the DG SANCO. The BENCH CAN project coordinated by the OEI should start

on January 2013 for a period of 36 months.

The application cover the priority area "Promote health" and in particular the action on prevention of major and rare diseases, providing information on cancer and pursuing efforts towards better cancer prevention and control. The general

objective of BENCH-CAN is to benchmark

*The general objective of BENCH-CAN is to benchmark comprehensive cancer care & yield best practice examples*

comprehensive cancer care & yield best practice examples in a way that contributes to improving the quality of interdisciplinary patient treatment. Differences in health systems performance in EU countries indicate sufficient room for improvement, contributing to a larger degree of disease & symptom free survival after primary treatment & prolonged symptom free metastatic disease. BENCH-CAN addresses the fundamental principles of 'Together for Health' to tackling the causes of cancer inequalities. BENCH CAN has been structured with 7 work packages and the expected outcomes are (i) 2 benchmark tools formatted for use in comprehensive cancer centres & cancer departments/units at general hospitals are piloted (ii) 11 pilot sites identify areas for improvement for quality of care & patient outcomes with improvement plans adopted (iii) a benchmark manual with budget impact formulae is produced for free access (iv) a roadmap for future assessments of comprehensive cancer care is produced. BENCH-CAN is adopted as a non-profit service available to cancer centres and services across the EU.

## OEI and European Alliance for Personalised Medicine

The OEI is taking part in a new pan-European initiative whose aim is to improve patient care in Europe by enabling access to personalised medicine. The European Alliance for Personalised Medicine (EAPM) was born from an initiative of the European Cancer Patient Coalition (ECPC) and was launched at the European Parliament on March 27th 2012.

The EAPM is issuing a call to help improve the regulatory environment to allow early patient access to personalised medicine and to boost research. The Alliance's Call to Action is based on 5 key topics, including regulations for patients' access, research and development, education and training of healthcare professionals, approaches to reimbursement

and HTA assessment and increasing patients' awareness and understanding of personalised medicine. Stakeholders include professional and patient advocacy groups with extensive scientific, clinical, caring and training expertise in Personalised Medicine and diagnostics, as well as leading academic institutions, industry and other expert stakeholders.

The OEI has been present since the launch of the initiative, co-organising with the ECPC the first meeting in Brussels on November 2011. It will now be involved primarily in the education and training topic, throughout the Education and Training WG Chair by Angelo Paradiso and involving alongside Mrs Birgitte Grube, President of the European Oncology Nursing Society, to implement new, patient-led education programmes for all healthcare professionals appropriate for the needs of the personalised medicine era.

## Proposal for the constitution of a European Collaborative Group on Cancer Survivorship (ECGCS)

The dramatic increase in the global population of cancer survivors predicted in the next few decades will have profound implications



this population in order to meet them more

for the individuals directly affected by cancer, as well as for each country's healthcare and welfare system, and it is imperative to increase our understanding of the unique needs of

effectively.

For this reason, on Friday 27th April 2012, survivorship experts from Europe and the USA, together with representatives of the European organisations OECI, ESO and ECPC, met at the National Cancer Research Centre "Giovanni Paolo II" in Bari, Italy, to discuss the founding of a European Collaborative Group on Cancer Survivorship (ECGCS). The idea for the group came from Dr. Vittorio Mattioli from the NCRC Bari, a OECI member. The group aims to involve clinicians, nurses, psychologists, healthcare planners, and policy makers to develop and share a cross-cultural plan of research, knowledge, comparison, education and dissemination in order to face the new challenges within the field of cancer survivorship in Europe. Since the meeting, the group has received tremendous support from individuals and organisations not only within Europe but also from Canada, the US and Australia, where similar initiatives are already in place.

## OECI European Award for cancer policies

The OECI has the pleasure to announce the establishment of an annual Award whose objectives are to celebrate excellence, achievements and/or public commitments in fighting cancer as well as raising awareness for the OECI, both politically and socially. The aim of this award is to celebrate

academic excellence and achievements or an extraordinary political commitment in the fight against cancer. Nominees will be cancer researchers, politicians or public figures whose role in the cancer fields has been particularly relevant. The winner will be invited to receive the award and present his/her work at the Annual OECI General Assembly. The winner will also become a honorary member of the OECI.

## Launching of a new Working Group on Cost-Benefit

The OECI is proud to announce the constitution of a Cost-Benefit Working Group that will



facilitate careful and explicit balancing of clinical benefits and financial impact of cancer treatments. The primary objectives

of the WG will be to demonstrate merits of cost-benefit analyses in oncology and to establish standards in budget impact analysis for OECI members. The WG will also pay attention to those recent developments in health economics, for example value based pricing, budget impact expertise, which have the special interest of the members. An interest call will be sent out soon to all members for their input. The OECI welcomes Dr. Lotte Steuten to whom the coordination of the new WG has been assigned.



## **OECI Accreditation and Designation System formally presented in Rome at the Ministry for Health: Italian CCCs ready to enter as a group the OECI recognition of excellence**

*The Italian Ministry for Health has decided to fund its national institutes through the accreditation process with a project named “Tailored Accreditation Model for Comprehensive Cancer Centres*

its national institutes through the accreditation

The Italian Comprehensive Cancer Centres (in Italy called cancer IRCCS) have recently made a novel step forward in their bid to obtain accreditation through the OECI Accreditation and Designation Programme. The Italian Ministry for Health has decided to fund

process with a project named “Tailored Accreditation Model for Comprehensive Cancer Centres: validation through the applicability of the OECI-based model to the Network of Cancer IRCCS of “Alleanza Contro il Cancro”, the Italian cancer network. The project will be coordinated by the Italian National Institute for Health “ISS” and managed by Dr Angelo Paradiso, Scientific Director of the National Cancer Research Centre “Giovanni Paolo II” in Bari, Italy. Nine national cancer centres will take part in it. On May 23rd 2012 the Working Group assigned to the Accreditation Project, comprising the Scientific Directors and Quality representatives of the participating institutes, met at the Ministry of Health in Rome for the kick-off meeting of the project. Dr. Mahasti Saghatchian (IGR Paris), Head of the OECI Accreditation Programme, and Dr. Massimo Casciello, General Director of Scientific Research and Technology at the Ministry were also present at the meeting. Italian Health Minister Prof. Renato Balduzzi took part by telephone. At the meeting, Dr. Saghatchian commented on the extreme originality of the project, currently the only one of its kind in Europe applying international criteria to all of its national institutes.

## **Instituto Português de Oncologia de Lisboa Francisco Gentil received the accreditation certificate**

During the OECI 2012 General Assembly in Berlin, the OECI accreditation certificate has been assigned to the Instituto Português

de Oncologia de Lisboa Francisco Gentil. Portugal is the first European country with all the recognised CCCs accredited (3 in number) to the OECI. Italy is proceeding in the same direction.



## Professor Giorgio Stanta engaged to present a working programme to re-launch the molecular pathobiology and biobanks WG



Following the merging of the Molecular Pathobiology and the Cancer Biobanks Working Groups on May 5th 2012, in Berlin, Prof. Giorgio Stanta was requested to coordinate the re-organisation process of the new WG. Giorgio Stanta is the coordinator of the IMPACTS group

([www.impactsnetwork.eu](http://www.impactsnetwork.eu)) which, since 2005, has developed validation and standardization of molecular methods in fixed and paraffin embedded tissues. This material represents the real clinical heterogeneity of cancer and the only tissues available in all the cancer centres and hospitals to perform molecular analysis. The programme of activities to be carried out by the new WG is also related to biomarkers validation in archive tissues, to the development of tissue biobanking networks, to the promotion of training, meetings and multicentric research projects involving other OECl Working Groups. The final goal of the WG will also be the promotion of a more effective collaboration among OECl pathologists and molecular biologists but not excluding colleagues from outside the network and re-launching the annual OECl meeting of the European Pathologists.

### START-OECl

## START-OECl attended the ECCO guidelines meeting in Brussels

On May 28th the OECl attended the first meeting organised in Brussels by ECCO to discuss the need of having European Cancer Guidelines. The OECl was represented by Dr. Lisa Licitra, chairperson of the OECl Activity START-OECl, the options and recommendations of cancer diagnosis and treatment. START-OECl agreed on the importance

*The OECl proposed START-OECl as being an evidence-based collection of chapters dealing with all tumours included the rare ones to function as an educational tool next to formally developed guidelines*

of collaboration among the European Cancer Societies in developing multidisciplinary guidelines. The OECl proposed START-OECl as being an evidence-based collection of chapters dealing with all tumours included the rare ones to function as an educational tool next to formally developed guidelines. Instead of endorsing disease and treatment-related guidelines provided by its own member society, START-OECl welcomes the idea of an ECCO body that provides multidisciplinary guidance and elaborates criteria for health care organisations to improve quality of care such as high volume referral and outcome based referral. ECCO with its multidisciplinary nature represents the only international body entitled to do so.



## Launching of a new Working Group OECl-Clinical Trial Enterprise (OECl-CTE)

*Clinical trials are essential to the development of new therapeutic interventions and data management operations of European cancer centres*

The purpose of a OECl clinical trial enterprise (OECl-CTE) can overcome a range of serious obstacles including growing complexity of trials, administrative barriers, regulatory constraints, expanding staffing requirements, increasing costs and lagging patient accrual. The OECl can address these challenges and put together a network for cancer centre clinical research leaders. The OECl-CTE will examine and share best practices that promote the efficient operation of cancer centre clinical research facilities, and can promote new initiatives responding academic questions in which other scientific organizations are less interested due to lack of financial support. The OECl-CTE is open exclusively to clinical research leaders from OECl centres (73). They possess a comprehensive view or knowledge of their centre's entire clinical

trials system, and they fill a variety of roles at their centres. Keys to the success of this new OECl-CTE will be the development of new tools and methods to share information across the OECl network of cancer centres, and the dissemination of proven means of effectiveness and best practice models that lead to increased access to new cancer therapies. Clinical trials are essential to the development of new therapeutic interventions and data management operations of European cancer centres. They are crucial for the design and implementation of prevention, early detection and treatment modalities, and ultimately, cancer cures. There can be an exchange and/or participation of other organisations as for example EORTC. To have a constructive and successful organisation, the OECl-CTE should have a Steering Committee, Special Interest Groups that are the key to the success of the Clinical Trial Enterprise(CTE) and successful partnerships (academics, industries, insurance companies, national- or European organisations etc.) Other societies which have a main activity within cancer as ECPC, ENS, ESO, ECCO can be linked and must have access to what OECl-CTE is performing. EU grants can be asked for if the goal is implementing translational research. Also important is how we can deal with our sister organization AACI, which has already experience in this approach and we can certainly collaborate and exchange data and permit cross over participation.

## 34th OECl General Assembly in Berlin – Joining the European Forum on Oncology - The partnership is

**confirmed  
for EFO  
2013  
Brussels**

The 2012 OECl General Assembly was organised in connection

*The interaction between EFO and OECl was considered positive and the next General Assembly will be organised in connection with the EFO meeting*

with the European Forum of Oncology (EFO) in Berlin on May 3rd -5th. Gesundheitsstadt Berlin had the main responsibility for the EFO and EurocanPlatform was responsible for the scientific content. The main focus on EFO is interaction between academia, industry and healthcare systems. Sharing vision and strategies is necessary for using resources and optimize innovation. This is in line with the OECl mission focusing on establishment of comprehensiveness and innovation in the cancer area and therefore the EFO replaced the traditional scientific meeting. The interaction between EFO and OECl was considered positive and the next General Assembly will be organised in connection with the EFO meeting that will take place in Brussels on May 13th -14th, 2013.



## 2013 OECI General Assembly - Brussels – May 15th 2013

During the last OECI General Assembly held in Berlin on May 5th, upon proposal of the President, the Delegates unanimously agreed to have the next General Assembly in Brussels on May 15th. The General Assembly will

be hosted by the University Centrum Brussel and by the Institut Jules Bordet, both full OECI members. The General Assembly will be preceded by the European Forum on Oncology where the OECI will collaborate for some aspects of the scientific program which is under the responsibility of the Eurocanplatform Network of Excellence. On May 14th the usual Gala Dinner will take place and the first OECI European Cancer Prize will be awarded.

## The OECI welcomes three new members

### The Danish Cancer Society Research Centre (DCRC)

On January 1st 2012, the Institutes of Cancer Biology and Cancer Epidemiology of the Danish Cancer Society merged into one organisational unit under the new name: The Danish Cancer Society Research Centre (DCRC). DCRC builds on three key ambitions, i.e., to combine complementary cancer research disciplines while maintaining scientific strongholds of the former two institutes, to feed a challenging and 'seamless' environment for the next generation of cancer researchers, and to communicate research results to the national and international community. The centre employs 180 scientists and technicians. The research opportunities and current work of DCRC scientists are evidently nourished by the advanced data infrastructure of the Scandinavian societies.

### The IRCCS Azienda Ospedaliera Universitaria San Martino – IST

On September 1st 2011, the Istituto Nazionale per la Ricerca sul Cancro of Genoa merged with the Azienda Ospedaliera Universitaria San Martino, giving origin to the new Institute "Azienda Ospedaliera Universitaria San Martino- Istituto Nazionale per la Ricerca sul Cancro", with USMI as official acronym. The Centre has already been recognised by the Ministry of Health as Italian Comprehensive Cancer Centre and Professor Manlio Ferrarini, full professor of medical oncology at the University of Genoa Medical School has been appointed Scientific Director of the new Cancer Centre. Thanks to the above merging, the

new Institute is improving research and care performances both in terms of quality and quantity. The USMI, taking profit from all the professional competences available at the University Medical School and at the General Hospital, improves the management of the single patient giving a concrete answer to the multidisciplinary and personalised approach to cancer patients. The new Institute, apart from the already existing departments of the previous cancer centre, welcomes now a division of haematology oncology and bone-marrow transplant centre, two additional medical oncology divisions, a nuclear medicine lab, a thoracic surgery division specialised for the treatment of lung cancers and a division of urology. The USMI hosts the coordination for international affairs of the Italian cancer network "Alleanza Contro il Cancro" and the Liaison Office of the Organisation of European Cancer Institutes.

### The National Koranyi Institute of TB and Pulmonology

The National Koranyi Institute of TB and Pulmonology is the largest thoracic disease centre of Hungary which guarantees high standards and innovative technologies in pulmonary oncology. It has approximately 300 available beds and each year six to seven hundred patients receive chemotherapy treatment. A separate thoracic surgery department, where 500-600 lung cancer operations are carried out each year, is operational in the Institute. The 24-bed capacity cancer palliative care unit also fulfils the requirements of hospice care services. Diagnostic background is provided by an independent pathology, modern imaging diagnostics and a clinical laboratory. A separate cancer research department is also operational.



## 2nd EACR-OECI Molecular Pathology Course

The training course took place in Amsterdam, from 7th to 9th May 2012 and was attended by 100 delegates from 16 European Countries and from Australia, Bosnia-Herzegovina, Canada, Iran Israel, Libya, Nigeria, Russian



Federation, Saudi Arabia.

The scientific programme included: current methods for assessment of molecular biomarkers, next generation sequencing, BRAF and KIT as

biomarkers in melanoma, KIT and novel targets in gastrointestinal stromal tumours, gene

signatures in breast cancer, genetic testing in colorectal and lung cancers, translocations in sarcomas and haematological malignancies, how to deliver molecular tests for clinical decision-making, novel findings in ovarian, endometrial and kidney cancers. The 'Molecular Pathology approach to cancer' training course has received 12 European CME credits from the Accreditation Council of Oncology in Europe recognising the high quality and value of the scientific and educational programme. Between 81% and 85% of delegates rated the course's coverage as 'Very good' or 'Excellent'. The general quality of the education offered by the course was rated 'Excellent' or 'Very good' by 89% of participants. 92% said that the information provided was 'Useful' or 'Very useful' to their work and practice techniques. The OECI sponsored the course also offering 10 grants to young pathologists but only 6 have been assigned. The applications for grants for the 3rd edition of the course in 2013 will also be open to applicants outside the OECI.

## Third edition of the Biobanking and Molecular Pathobiology training course in Cluj

The ESO-OECI Course on Cancer Molecular Pathobiology in the Clinics, took place in the beautiful old city of Cluj-Napoca in Romania from 18th to 20th April 2012. Organised



by the OECI Education & Training Working Group together with the local host, the Oncology Institute Ion Chiricuta and the European School of Oncology, the

course brought together eminent pathologists and oncologists from the USA and from Europe as well as many young local medical students to share the latest knowledge in the most challenging fields of cancer diagnostics and treatments. In particular, the learning objectives focused on the specific role and value of pathology versus molecular biology for cancer diagnosis and response to treatment, the molecular mechanisms of cancer for clinical evaluation, molecular oncology tests, the next generation technologies underlying molecular diagnostics today and new trends in clinical trials. A special session was dedicated to virtual microscopy slide evaluation as a practical approach for pathologists and specialists in the field. The impressive scientific programme, engaging speakers and the warmth of the Romanian hosts made for an extremely successful event which was appreciated by all 175 participants present.

## Survivorship conference in Bari

From 26th to 28th April 2012, close to 100 researchers and students working in the field of Cancer Survivorship in 12 EU countries, Turkey and the US met in Bari (Italy) for the ESO-OECI

International Symposium on Cancer Survivorship, "State of the Art of Cancer Survivorship Research". Organised by the OECI Education &

Training Group, the National Cancer Research Centre "Giovanni Paolo II" (host institute) and The Netherlands Cancer Institute NKI-AVL, the symposium was organised around three key themes: Ageing, Comorbidity and Symptoms; Psychosocial Health: Diagnosis and Treatment; and Rehabilitation and Physical Activity, and aimed to provide a platform in which to compare European and American knowledge and practice in cancer survivorship. An impressive faculty of speakers delivered an excellent series of presentations, and the participants also enjoyed the many animated post-presentation discussions. Four young poster presenters were awarded prizes sponsored by ESO, OECI and the AIOM, the Italian Association of Medical Oncology.

*The symposium was organised around three key themes and aimed to provide a platform in which to compare European and American knowledge and practice in cancer survivorship*



### ACCREDITATION AND DESIGNATION

Starting from June 2012  
the OECI Accreditation and  
Designation system is also open  
to non-OECI members

For more details contact  
[oeci@oeci.eu](mailto:oeci@oeci.eu)



**Mahasti  
Saghatchian**

**Accreditation  
and Designation  
Chairperson**

The OECI Accreditation/Designation programme aims at defining consensual European quality standards and criteria supporting the concept of Comprehensive Cancer Centre with integration of care, research and education.

If your Institute is interested in applying for the programme, please find the application form at:

**<http://oeci.selfassessment.nu>**

**Austria**

- Comprehensive Cancer Center Vienna ([www.ccc.ac.at](http://www.ccc.ac.at))

**Belgium**

- Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels ([www.bordet.be](http://www.bordet.be))
- Oncologic Center, UZBrussel, Brussels ([www.uzbrussel.be](http://www.uzbrussel.be))
- Cliniques Universitaire Saint-Luc (Centre du Cancer), Brussels ([www.centreducancer.be](http://www.centreducancer.be); [www.saintluc.be](http://www.saintluc.be))

**Bulgaria**

- National Oncological Hospital, Sofia ([www.onco-bg.com](http://www.onco-bg.com))

**Czech Republic**

- Masaryk Memorial Cancer Institute, Brno ([www.mou.cz](http://www.mou.cz))

**Denmark**

- Danish Cancer Society, Institute of Cancer Biology, Copenhagen ([www.cancer.dk](http://www.cancer.dk))

**Estonia**

- North Estonia Medical Centre, Tallinn ([www.regionaalhaigla.ee](http://www.regionaalhaigla.ee))
- Tartu University Hospital, Tartu ([www.kliinikum.ee](http://www.kliinikum.ee))

**Finland**

- Helsinki University Central Hospital, Helsinki ([www.hus.fi](http://www.hus.fi))

**France**

- Centre Alexis Vautrin, Nancy ([www.alexisvautrin.fr](http://www.alexisvautrin.fr))
- Centre G.F. Leclerc, Dijon ([www.cgfl.fr](http://www.cgfl.fr))
- Centre Leon Berard, Lyon ([oncora1.lyon.fnclcc.fr](http://oncora1.lyon.fnclcc.fr))
- Centre Paul Strauss, Strasbourg ([www.centre-paul-strauss.fr](http://www.centre-paul-strauss.fr))
- Institut Curie, Paris ([www.curie.fr](http://www.curie.fr))
- Institut Gustave Roussy, Villejuif ([www.igr.fr](http://www.igr.fr))
- Centre Antoine Lacassagne, Nice ([www.centreantoinelacassagne.org](http://www.centreantoinelacassagne.org))
- Centre Henri Becquerel, Rouen ([www.becquerel.fr](http://www.becquerel.fr))
- Centre Paul Papin CRLCC, Angers ([www.centrepaulpapin.org](http://www.centrepaulpapin.org))
- Institut Sainte Catherine, Avignon ([www.institut-sainte-catherine.org](http://www.institut-sainte-catherine.org))
- Institut Claudius Regaud, Toulouse ([www.claudiusregaud.fr](http://www.claudiusregaud.fr))

**Germany**

- Deutsches Krebsforschungszentrum, Heidelberg ([www.dkfz.de](http://www.dkfz.de))
- University Cancer Centre Dresden Carl Gustav Carus, Dresden ([www.uniklinikum-dresden.de](http://www.uniklinikum-dresden.de))
- Charité Comprehensive Cancer Center, Berlin ([cccc.charite.de](http://cccc.charite.de))

**Greece**

- Metaxa Cancer Hospital of Piraeus, Piraeus ([www.metaxa-hospital.gr](http://www.metaxa-hospital.gr))
- Anticancer Oncological Hospital of Athens «Saint Savvas», Athens ([www.imasavas.gr](http://www.imasavas.gr))
- Agii Anargiri General Oncological Hospital of Kifissia ([www.onco.gr](http://www.onco.gr))

**Hungary**

- National Institute of Oncology, Budapest ([www.oncol.hu](http://www.oncol.hu))
- National Koranyi Institute of TB and Pulmonology ([www.koranyi.hu](http://www.koranyi.hu))

**Italy**

- Azienda Ospedaliera Arcispedale S. Maria Nuova, Reggio Emilia ([www.asmn.re.it](http://www.asmn.re.it))
- Centro di Riferimento Oncologico (CRO) - Istituto Nazionale Tumori, Aviano ([www.cro.it](http://www.cro.it))
- European Institute of Oncology (IEO), Milan ([www.ieo.it](http://www.ieo.it))
- European School of Oncology (ESO), Milan ([www.eso.net](http://www.eso.net))
- Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan ([www.istitutotumori.mi.it](http://www.istitutotumori.mi.it))
- Fondazione San Raffaele, Milan ([www.sanraffaele.org](http://www.sanraffaele.org))
- IRCCS Azienda Ospedaliera Universitaria San Martino – IST – Istituto Nazionale per la Ricerca sul Cancro, Genoa ([www.hsanmartino.it](http://www.hsanmartino.it))
- Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione 'G.Pascale', Naples ([www.fondazionepascale.it](http://www.fondazionepascale.it))
- Istituto Regina Elena (IRE), Rome ([www.ifo.it](http://www.ifo.it))
- Istituto Superiore di Oncologia (ISO), Italy ([www.consorzioiso.it](http://www.consorzioiso.it))
- Istituto Tumori Giovanni Paolo II, Bari ([www.oncologico.bari.it](http://www.oncologico.bari.it))
- Istituto di Ricerche Farmacologiche Mario Negri IRFMN, Milan ([www.marionegri.it](http://www.marionegri.it))
- Istituto di Ricerca e Cura del Cancro di Candiolo, Turin ([www.ircc.unito.it](http://www.ircc.unito.it))
- Istituto Oncologico Veneto (IOV), Padua ([www.ioveneto.it](http://www.ioveneto.it))
- Istituto FIRC di Oncologia Molecolare (IFOM), Milan ([www.ifom-firc.it](http://www.ifom-firc.it))
- Centro di Riferimento Oncologico della Basilicata (CROB), Potenza ([www.crob.it](http://www.crob.it))
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola - Forlì ([www.irst.emr.it](http://www.irst.emr.it))

**Lithuania**

- Institute of Oncology, Vilnius University, Vilnius ([www.loc.lt](http://www.loc.lt))

**Norway**

- Rikshospitalet-Radiumhospitalet Medical Center, Oslo ([www.rikshospitalet.no](http://www.rikshospitalet.no))

**Poland**

- Wielkopolskie Cancer Centre, Poznan ([www.wco.pl](http://www.wco.pl))

**Portugal**

- Instituto Portugues de Oncologia Francisco Gentil EPE do Porto, Porto ([www.ipoporto.min-saude.pt](http://www.ipoporto.min-saude.pt))
- Instituto Portugues de Oncologia Francisco Gentil EPE do Coimbra, Coimbra ([www.croc.min-saude.pt](http://www.croc.min-saude.pt))
- Instituto Portugues de Oncologia Francisco Gentil EPE do Lisboa, Lisbon ([www.ipolisboa.min-saude.pt](http://www.ipolisboa.min-saude.pt))

**Romania**

- Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca ([www.iocn.ro](http://www.iocn.ro))
- Institute of Oncology «Prof. Dr. Al Trestioreanu», Bucharest ([www.iob.ro](http://www.iob.ro))

**Russia**

- Blokhin Russian Cancer Research Centre, Moscow ([www.ronc.ru](http://www.ronc.ru))
- Clinical Cancer Centre, Kazan

**Serbia - Montenegro**

- Institute of Oncology Sremska Kamenica Novi Sad, Sremska Kamenica ([www.onk.ns.ac.rs](http://www.onk.ns.ac.rs))

**Slovakia**

- Slovak Comprehensive Cancer Centre, Bratislava ([www.exon.sav.sk](http://www.exon.sav.sk))

**Slovenia**

- Institute of Oncology Ljubljana, Ljubljana ([www.onko-i.si](http://www.onko-i.si))

**Spain**

- Centro Nacional de Investigaciones Oncologicas, Madrid ([www.cnio.es](http://www.cnio.es))
- Institut Català d'Oncologia, Barcelona ([www.iconcologia.net](http://www.iconcologia.net))
- Instituto Madrilenio de Oncologia (IMO), Madrid ([www.grupoimo.com](http://www.grupoimo.com))
- Fundacion Instituto Valenciano de Oncologia (IVO), Valencia ([www.ivo.es](http://www.ivo.es))

**Sweden**

- Sahlgrenska University Hospital, Göteborg ([sahlgrenska.se](http://sahlgrenska.se))
- The Karolinska University Hospital and Institute, Stockholm ([ki.se](http://ki.se))

**Switzerland**

- Istituto Oncologico Svizzera Italiana (IOSI), Bellinzona ([www.eoc.ch](http://www.eoc.ch))

**The Netherlands**

- Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam ([www.erasmusmc.nl](http://www.erasmusmc.nl))
- Integral Kankercentrum Noord-Nederland, Groningen ([www.ikno.nl](http://www.ikno.nl))
- The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam ([www.nki.nl](http://www.nki.nl))
- Maastricht University Medisch Centrum, Maastricht ([www.mumc.nl](http://www.mumc.nl); [www.azm.nl](http://www.azm.nl))

**Turkey**


- Dokuz Eylul University, Institute of Oncology, Izmir ([www.deu.edu.tr](http://www.deu.edu.tr))

**Ukraine**

- R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kiev ([www.nas.gov.ua](http://www.nas.gov.ua))

**United Kingdom**

- Cancer Research UK Cambridge Research Institute, Cambridge ([www.cambridgecancer.org.uk](http://www.cambridgecancer.org.uk))
- Christie Hospital NHS Foundation Trust, Manchester ([www.christie.nhs.uk](http://www.christie.nhs.uk))
- King's Health Partners Integrated Cancer Centre, London ([www.guysandstthomas.nhs.uk](http://www.guysandstthomas.nhs.uk))







**President**

Wim H. van Harten  
Amsterdam, The Netherlands



**President Elect**

Alexander Eggermont  
Paris, France



**Past President**

Marco A. Pierotti  
Milan, Italy



**Executive Secretary**

Guy Storme  
Brussels, Belgium



**Treasurer**

José Maria Laranja Pontes  
Porto, Portugal



**Elected Member**

Julio Celis  
Copenhagen, Denmark



**Special Assistant to the President  
Liaison Office Coordinator**

Claudio Lombardo - Genoa, Italy

**OECD-EEIG Central Office**  
c/o Fondation Universitaire  
11, Rue d'Egmont  
B-1000, Brussels, Belgium  
Phone: +32 2 512 0146

**[www.oecd.eu](http://www.oecd.eu)**  
**For membership contact:**  
**[oecd@oecd.eu](mailto:oecd@oecd.eu)**